Gastric Cancer Pipeline, Treatment Drugs, Clinical Trials and Companies 2024 (Updated)

DelveInsight's, "Gastric Cancer Pipeline Insight 2024" report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Gastric Cancer Research. Learn more about our innovative pipeline today! @ Gastric Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Gastric Cancer Pipeline Report
• In December 2024:- Camurus AB- The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
• In December 2024:- Merck Sharp & Dohme LLC- The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen]) versus placebo in combination with chemotherapy (FP or CAPOX regimens) in the treatment of human epidermal growth factor receptor 2 (HER2) negative advanced gastric or GEJ adenocarcinoma in adult participants.
• In December 2024:- Jazz Pharmaceuticals- This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
• DelveInsight's Gastric Cancer pipeline report depicts a robust space with 200+ active players working to develop 220+ pipeline therapies for Gastric Cancer treatment.
• The leading Gastric Cancer Companies such as BeiGene, Linton Pharm Co. Ltd., RAPT Therapeutics, Leap Therapeutics, Idience, Bolt Biotherapeutics, Hubro Therapeutics, Immunocore, Ambrx, Hangzhou DAC Biotech, Beijing Immunoah Pharma Tech, Base Therapeutics, Nanjing KAEDI Biotech, HiberCell, Transcenta Holding, Suzhou Zelgen Biopharmaceuticals, Daiichi Sankyo, Ipsen, Alligator Bioscience, Bristol Myers Squibb, Jiangsu Hengrui Medicine, Shanghai Junshi Biosciences, ImmunoACT, and others.
• Promising Gastric Cancer Therapies such as XRP6976, Catumaxomab, Zanidatamab, Tislelizumab, Trastuzumab, Pembrolizumab, Cisplatin, 5-fluorouracil, and others.

Stay informed about the cutting-edge advancements in Gastric Cancer treatments. Download for updates and be a part of the revolution in care @ Gastric Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastric Cancer Emerging Drugs Profile

• Tislelizumab: BeiGene
Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGene's immuno-oncology biologics program and is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. The China National Medical Products Administration (NMPA) has approved tislelizumab in six indications. Including full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy, for first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and for second- or third-line treatment of patients with locally advanced or metastatic NSCLC who progressed on prior platinum-based chemotherapy. Tislelizumab is not approved for use outside of China. Currently the drug is registered for the treatment of gastric cancer.

• Catumaxomab: Linton Pharm Co. Ltd.
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. Currently the drug is in Phase III stage of development for the treatment of gastric cancer.

• Tivumecirnon: RAPT Therapeutics
Tivumecirnon is a small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues. Treg represent a dominant pathway for downregulating the immune response, generally correlate with poor clinical outcomes and may limit the effectiveness of currently available therapies such as checkpoint inhibitors. Tivumecirnon may restore naturally occurring antitumor immunity alone and may synergize with a variety of both conventional and immune-based therapies, such as radiation, chemotherapy, checkpoint inhibitors, immune stimulators, cancer vaccines and adoptive T cell therapy. Currently the drug is in Phase II stage of development for the treatment of gastric cancer.

• DKN-01: Leap Therapeutics
DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling, a signaling pathway frequently implicated in tumorigenesis and suppressing the immune system. DKK1 has an important role in tumor cell signaling and in mediating an immuno-suppressive tumor microenvironment through enhancing the activity of myeloidderived suppressor cells and downregulating NK ligands on tumor cells. DKN-01 has received Orphan Drug Designation for the treatment of gastric and gastroesophageal junction cancer from the U.S. Food and Drug Administration. Currently the drug is in Phase II stage of development for the treatment of gastric cancer.

• Venadaparib: Idience
Venadaparib (IDX-1197) is a potent PARP inhibitor that prevents the repair of DNA single-strand breaks (SSB) and promote the conversion of SSB to double-stranded breaks (DSB), which ultimately leads to synthetic lethality in cancer cells. IDX-1197 is under clinical development targeting multiple solid tumors as a monotherapy (including maintenance) and for combination with other anti-cancer agents. Currently the drug is in Phase I stage of development for the treatment of gastric cancer.

• BDC-4182: Bolt Biotherapeutics
BDC-4182 is Bolt's next-generation ISAC candidate targeting Claudin 18.2, a novel target in oncology, with programs in development for the treatment of gastric or gastroesophageal junction cancer and pancreatic cancer. Currently the drug is in Preclinical stage of development for the treatment of gastric cancer.

Learn more about Gastric Cancer Drugs opportunities in our groundbreaking Gastric Cancer Research and development projects @ Gastric Cancer Unmet Needs- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastric Cancer Companies
BeiGene, Linton Pharm Co. Ltd., RAPT Therapeutics, Leap Therapeutics, Idience, Bolt Biotherapeutics, Hubro Therapeutics, Immunocore, Ambrx, Hangzhou DAC Biotech, Beijing Immunoah Pharma Tech, Base Therapeutics, Nanjing KAEDI Biotech, HiberCell, Transcenta Holding, Suzhou Zelgen Biopharmaceuticals, Daiichi Sankyo, Ipsen, Alligator Bioscience, Bristol Myers Squibb, Jiangsu Hengrui Medicine, Shanghai Junshi Biosciences, ImmunoACT, and others.

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Gastric Cancer Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Gastric Cancer treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Gastric Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Gastric Cancer Pipeline Report
• Coverage- Global
• Gastric Cancer Companies- BeiGene, Linton Pharm Co. Ltd., RAPT Therapeutics, Leap Therapeutics, Idience, Bolt Biotherapeutics, Hubro Therapeutics, Immunocore, Ambrx, Hangzhou DAC Biotech, Beijing Immunoah Pharma Tech, Base Therapeutics, Nanjing KAEDI Biotech, HiberCell, Transcenta Holding, Suzhou Zelgen Biopharmaceuticals, Daiichi Sankyo, Ipsen, Alligator Bioscience, Bristol Myers Squibb, Jiangsu Hengrui Medicine, Shanghai Junshi Biosciences, ImmunoACT, and others.
• Gastric Cancer Therapies- XRP6976, Catumaxomab, Zanidatamab, Tislelizumab, Trastuzumab, Pembrolizumab, Cisplatin, 5-fluorouracil, and others.
• Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Gastric Cancer Pipeline on our website @ Gastric Cancer Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/gastric-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Gastric Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Gastric Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Catumaxomab: Linton Pharm Co. Ltd.
9. Mid Stage Products (Phase II)
10. Tivumecirnon: RAPT Therapeutics
11. Early Stage Products (Phase I)
12. Venadaparib: Idience
13. Preclinical and Discovery Stage Products
14. BDC-4182: Bolt Biotherapeutics
15. Inactive Products
16. Gastric Cancer Key Companies
17. Gastric Cancer Key Products
18. Gastric Cancer- Unmet Needs
19. Gastric Cancer- Market Drivers and Barriers
20. Gastric Cancer- Future Perspectives and Conclusion
21. Gastric Cancer Analyst Views
22. Gastric Cancer Key Companies
23. Appendix

List of Top Selling Market Research Reports in 2024

attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
external defibrillators market- https://www.delveinsight.com/report-store/external-defibrillators-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
ornithine transcarbamylase deficiency market- https://www.delveinsight.com/report-store/ornithine-transcarbamylase-deficiency-otc-deficiency-market
pediatric neuroblastoma market- https://www.delveinsight.com/report-store/neuroblastoma-market
schistosomiasis market- https://www.delveinsight.com/report-store/schistosomiasis-market
tcr therapy market- https://www.delveinsight.com/report-store/tcr-therapy-market
uk healthcare report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
vascular access devices market https://www.delveinsight.com/report-store/vascular-access-device-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
artificial disc market- https://www.delveinsight.com/report-store/artificial-disc-market
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-market
respiratory syncytial virus market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
shingles market - https://www.delveinsight.com/report-store/shingles-market
short bowel syndrome drug market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
cxcr inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
short bowel syndrome market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
catheter stabilization devices market- https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
celiac disease market- https://www.delveinsight.com/blog/celiac-disease-market-key-companies
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
pulmonary emphysema market- https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-treatment-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
nk cell therapy market- https://www.delveinsight.com/blog/nk-cell-therapy-in-cancer-treatment
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
healthcare consulting solutions- https://www.delveinsight.com/consulting
skin neoplasm market- https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
meibomian gland dysfunction market- https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight
dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight
testicular neoplasm market- https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market
microscopy device market- https://www.delveinsight.com/sample-request/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.